Therapeutic Asset Ratings

147 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Entrectinib Neuroendocrine Neoplasm	Hoffmann-La Roche	P2	CCC (51)
ro7269162 Alzheimer Disease	Hoffmann-La Roche	P2	CCC (51)
Tiragolumab Rectal Carcinoma	Hoffmann-La Roche	P2	CCC (51)
Iberdomide Non-Hodgkin Lymphoma	Hoffmann-La Roche	P1/2	CCC (51)
immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8) latent myostatin complex], humanized monoclonal antibody; Obesity Disorder	Hoffmann-La Roche	P2	CCC (50)
Inavolisib Colorectal Cancer	Hoffmann-La Roche	P2	CCC (50)
Inavolisib Neoplasm	Hoffmann-La Roche	P2	CCC (50)
Ladiratuzumab Vedotin Breast Cancer	Hoffmann-La Roche	P2	CCC (50)
ro7247669 Non-Small Cell Lung Carcinoma	Hoffmann-La Roche	P2	CCC (50)
ro7795081 Obesity Disorder	Hoffmann-La Roche	P2	CCC (50)
ro7771950 HER2 Positive Breast Carcinoma	Hoffmann-La Roche	P2/3	CCC (50)
Tocilizumab Neoplasm	Hoffmann-La Roche	P1/2	CCC (49)
Balovaptan Ischemic Stroke	Hoffmann-La Roche	P2	CCC (48)
Belvarafenib Neoplasm	Hoffmann-La Roche	P2	CCC (48)
Divarasib Neoplasm	Hoffmann-La Roche	P2	CCC (48)
Entrectinib Renal Cell Carcinoma	Hoffmann-La Roche	P2	CCC (48)
Inavolisib Metastatic Prostate Carcinoma	Hoffmann-La Roche	P2	CCC (48)
ro7247669 Renal Cell Carcinoma	Hoffmann-La Roche	P2	CCC (48)
ALECTINIB ALK Fusion-positive Solid or CNS Tumors	Hoffmann-La Roche	P1/2	CCC (48)
Inavolisib Estrogen-Receptor Positive Breast Cancer	Hoffmann-La Roche	P1/2	CCC (48)
ro7247669 Hepatocellular Carcinoma	Hoffmann-La Roche	P1/2	CCC (48)
Samuraciclib Estrogen-Receptor Positive Breast Cancer	Hoffmann-La Roche	P1/2	CCC (48)
Tiragolumab Follicular Lymphoma	Hoffmann-La Roche	P1/2	CCC (48)
Zirconium Zr 89 Crefmirlimab Berdoxam Non-Hodgkins Lymphoma	Hoffmann-La Roche	P1/2	CCC (48)
Tiragolumab Neoplasm	Hoffmann-La Roche	P2	CC (47)

Showing 76 to 100 of 147 assets

PreviousPage 4 of 6Next